MedTrace Logo

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

NCT06251973 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-05-15

No results posted yet for this study

Summary

Participants will receive study treatment with agenT-797, botensilimab, balstilimab, ramucirumab, and paclitaxel. When participants start each agent will depend on how their disease is affecting them.

Conditions

  • Metastatic Esophageal Carcinoma
  • Advanced Unresectable Gastric Adenocarcinoma
  • Metastatic Gastric Cancer
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Metastatic Esophageal Cancer
  • Metastatic Esophageal Adenocarcinoma
  • Metastatic Gastric Adenocarcinoma
  • Metastatic Gastric Carcinoma
  • Unresectable Esophageal Cancer
  • Unresectable Esophageal Adenocarcinoma
  • Unresectable Gastric Carcinoma
  • Unresectable Gastric Adenocarcinoma
  • Unresectable Gastroesophageal Junction Adenocarcinoma

Interventions

BIOLOGICAL

AgenT-797

AgenT-797 is an investigational product, composed of allogeneic human unmodified iNKT cells, isolated from mononuclear cell aphaeresis units from healthy donors

BIOLOGICAL

Botensilimab

Botensilimab is a novel, human, Fc-engineered IgG1 anti-CTLA-4 antibody

DRUG

Balstilimab

Botensilimab is supplied as a sterile, single-use solution for IV administration

DRUG

Ramucirumab

Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.

DRUG

Paclitaxel

Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.

Sponsors & Collaborators

Principal Investigators

  • Yelena Janjigian, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-01
Primary Completion
2027-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06251973 on ClinicalTrials.gov